Pen­ny stock play­er Adamis gets an­oth­er CRL for high-dose nalox­one as shares crater

The FDA has once again shut the door on mi­cro cap biotech Adamis Phar­ma­ceu­ti­cals’ high dose nalox­one in­jec­tion.

Reg­u­la­tors hand­ed down the pro­gram’s sec­ond CRL in near­ly 12 months, Adamis an­nounced Mon­day, send­ing the pen­ny stock spi­ral­ing. The new re­jec­tion came as a re­sult of new chem­istry, man­u­fac­tur­ing and con­trols is­sues, though Adamis not­ed that none of the prob­lems stemmed from the “ex­tracta­bles and leach­ables test­ing” prob­lems that caused the first thumbs down.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.